• 4-Hydroxytamoxifen Protocol and QC Guide

  2026-09-29

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled cell, cancer, apoptosis, and cardiac myocyte workflows. It is appropriate for studies that can accommodate DMSO, but should not be selected when water or ethanol dissolution, long-term solution storage, or an already validated compound-specific dosing protocol is required.

• Linarin, Cyclin A2, and NSCLC Cell-Cycle Arrest

  2026-09-29

  A 2026 study identifies the Herba Patriniae flavonoid linarin as an inhibitor of non-small-cell lung cancer cell growth, linking its activity to G0/G1 arrest, senescence, apoptosis, and reduced Cyclin A2, Cyclin B1, and CHEK1 signaling. The work combines network pharmacology with EdU-based proliferation analysis, cell-cycle profiling, senescence assays, molecular docking, and immunoblotting to connect a botanical component with a defined cell-cycle phenotype.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-28

  Saito and colleagues developed a streamlined three-dimensional culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. The resulting organoid-derived epithelial cells contained differentiated intestinal cell types and displayed cytochrome P450 and transporter activities, supporting more human-relevant in vitro pharmacokinetic studies.

• Z-DEVD-FMK Workflows for Cell-Death Studies

  2026-09-28

  Z-DEVD-FMK is a cell-permeable, irreversible caspase-3 inhibitor for testing executioner-caspase involvement in apoptosis assays, with additional activity against other caspases and calpains. This guide covers practical dosing and solubility choices—and explains why it is a pathway-comparison tool, not a direct inhibitor for studying caspase-1-driven pyroptosis.

• SuperSignal ECL Kit Ultrasensitive for Western Blots

  2026-09-27

  The SuperSignal ECL Chemiluminescent Substrate Detection Kit supports HRP-based Western blot protein detection, including femtogram-level bands under optimized conditions. This article explains how the SuperSignal ECL Kit Ultrasensitive can fit a CRSwNP ALOX5 research workflow while distinguishing product specifications from findings reported in the disease study.

• Spatially Concentrated ABEs Correct PLP1 Mutations

  2026-09-26

  The study introduces spatially concentrated adenine base editors that improve editing in oligodendrocytes by recruiting the deaminase to target sites, rather than simply increasing its catalytic activity. The compact cABE-2.0 design corrected a disease-associated PLP1 mutation in oligodendrocytes and improved myelination-related outcomes in the reported experiments, while reducing transcriptome-wide RNA off-target effects.

• BX795 Workflows for PDK1 and Innate Immunity

  2026-09-25

  BX795 is a practical probe for studying PDK1 alongside TBK1/IKKε-dependent immune signaling, but its multi-kinase activity makes careful controls essential. This workflow connects kinase measurements with interferon and autophagy readouts, including lessons from recent HBV research.

• From Human Nociceptors to Trustworthy RNA Readouts

  2026-09-25

  Human sensory-neuron studies are raising the bar for translational evidence: functional phenotypes need molecular readouts that are equally dependable. This article connects a human DRG study of MNK inhibition with practical strategies for controlling DNA carryover in RNA workflows, including the role and limits of DNase I (RNase-free).

• HAUS1 in HCC: Prognostic Signal and Immune Context

  2026-09-24

  A 2024 study integrated public tumor datasets with siRNA experiments to examine HAUS1 expression, clinical associations, immune features, and malignant cell behaviors in hepatocellular carcinoma (HCC). Its findings nominate HAUS1 as a candidate biomarker and experimental target, while leaving clinical utility and the proposed immunotherapy relevance to be tested in independent cohorts and prospective studies.

• BMS-777607: c-Met Inhibitor Workflows

  2026-09-24

  Use BMS-777607 to probe MET-family signaling in cancer models, with a practical workflow for measuring target engagement and troubleshooting assay results. Its possible use in hiPSC-derived megakaryocyte studies is exploratory: the latest differentiation study identifies a useful context, not proof that BMS-777607 improves platelet production.

• BMN 673: HCC Splicing Workflows and PARP Inhibition

  2026-09-23

  BMN 673 (Talazoparib) offers a potent way to test how spliceosome disruption and DNA-repair defects shape PARP inhibitor response. This guide turns a recent hepatocellular carcinoma study into a cautious, practical workflow for dose-response, splicing, and combination experiments.

• Chronic Cabozantinib Adaptation in RCC Phosphoproteomes

  2026-09-23

  This study distinguishes acute from chronic Cabozantinib adaptation in renal cell carcinoma using quantitative phosphoproteomics and matched motility assays. It shows that prolonged exposure preserves suppression of MET activation-loop phosphorylation while selectively remodeling adhesion-, stress-, and MAPK/AP-1-associated signaling linked to context-dependent migration and invasion.

• DNase I (RNase-free) for Assay Integrity

  2026-09-22

  DNase I (RNase-free) is more than an RNA cleanup reagent: its cation-dependent cleavage chemistry can shape how tumor-microenvironment experiments are interpreted. This article connects ribonuclease-free DNase I use with lactate-driven colorectal cancer resistance research, chromatin handling, and defensible assay design.

• CP-673451: Selective PDGFRα/β Inhibitor Workflow

  2026-09-22

  CP-673451 enables targeted interrogation of PDGFRα/β signaling across phosphorylation, angiogenesis, and xenograft assays. Its nanomolar cellular activity and relative sparing of VEGFR and c-Kit support cleaner mechanism-of-action studies, including ATRX-stratified glioma research.

• DNase I (RNase-free): Protecting Assay Signal

  2026-09-21

  DNase I (RNase-free) supports cleaner RNA, RT-PCR, and transcription workflows by removing residual DNA without treating nucleic-acid cleanup as an afterthought. This article connects nuclease selection to orthogonal assay design, using human sensory-neuron research to show why pre-analytical control matters.

8459 records 1/564 page Next 12345 下5页 Last page